Fundraising Fox

XDemics

Novato, US · Delaware corporation

XDemics develops cell culture and biomanufacturing technologies for generating mammalian cells at high densities for advanced therapy production. The company's HDCR platform and related products enable researchers and GMP facilities to produce T cell, stem cell, and viral-based therapies with improved quality and consistency.

BiotechDeep TechHardwareHealthtechMedical Devices

Founders & leadership

CT
Christopher ThanosinChairman and CEO

Board

CCColin Cook
Colin CookinCo-founder and CTO
NB
Nicole BergmaninBoard director

Reported raises · per SEC filings

Form D private placements

$14.8M disclosed across 3 rounds · 2024–2025

▶$7.4MraisedFeb 2026 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nicole BergmanDirector
  • Colin CookDirector
  • Christopher ThanosExecutive Officer, Director
Offering amount
$7.4M
Amount sold
$7.4M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedDec 2024 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nicole BergmanDirector
  • Colin CookDirector
  • Christopher ThanosExecutive Officer, Director
Offering amount
$7.6M
Amount sold
$5.5M
First sale
Nov 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.9MraisedSep 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Colin CookDirector
  • Christopher ThanosExecutive Officer, Director
  • Nicole BergmanDirector
Offering amount
$1.9M
Amount sold
$1.9M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Molecular Devices18 shared keywordsMolecular Devices provides automated systems and services to support 3D cell biology research workflows, including cell culture automation, organoid expansion services, and imaging analysis tools for drug discovery and preclinical research.

Companies competing with XDemics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

XDemics Corporation - BIO Investment & Growth Summit 2026bigs.bio.org · Mar 2026Sell or Invest in XDemics Stock Pre-IPOnasdaqprivatemarket.com · Nov 2025

Frequently asked questions

What does XDemics do?
XDemics develops cell culture and biomanufacturing technologies for generating mammalian cells at high densities for advanced therapy production. The company's HDCR platform and related products enable researchers and GMP facilities to produce T cell, stem cell, and viral-based therapies with improved quality and consistency.
How much funding has XDemics raised?
XDemics has disclosed $14.8M raised across 3 rounds.
Where is XDemics headquartered?
XDemics is headquartered in Novato, US.